1-[4-(6-fluoro-3-oxo-10-aza-3-azoniatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-10-yl)phenyl]-N-methylmethanamine;phosphoric acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1-[4-(6-fluoro-3-oxo-10-aza-3-azoniatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-10-yl)phenyl]-N-methylmethanamine;phosphoric acid
• 化学式: C19H24FN3O5P+
• 分子量: 424.4
• InChiKey: OIHUJZIOZLFCGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS
  申请人：Senhwa Biosciences, Inc.

  公开号：US20170166590A1

  公开（公告）日：2017-06-15

  The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.

  本发明包括2-(4-甲基-[1,4]二氮杂环己烷-1-基)-5-氧代-5H-7-硫-1,11b-二氮杂苯并[c]芴-6-羧酸（5-甲基吡嗪-2-基甲基）-酰胺的结晶形式，以及2-(4-甲基-[1,4]二氮杂环己烷-1-基)-5-氧代-5H-7-硫-1,11b-二氮杂苯并[c]芴-6-羧酸（5-甲基吡嗪-2-基甲基）-酰胺的盐和/或溶剂结晶形式。此外，本发明提供包含这些结晶形式以及其组合物的组合物，并提供这些结晶形式及其组合物的治疗用途。
• CRYSTALLINE FORMS OF QUINOLINE ANALOGS AND SALTS THEREOF, COMPOSITIONS, AND THEIR METHODS FOR USE
  申请人：Senhwa Biosciences, Inc.

  公开号：US20210046082A1

  公开（公告）日：2021-02-18

  The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I). Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.

  本发明涉及2-(4-甲基-[1,4]二氮杂环庚烷-1-基)-5-氧代-5H-7-硫-1,11b-二氮杂苯并[c]芴-6-羧酸(5-甲基吡嗪-2-基甲基)-酰胺(化合物I)的晶体形式。此外，本发明提供了包含这些晶体形式的组合物以及这些晶体形式和组合物的治疗用途。
• TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS, AND METHODS FOR THEIR USE
  申请人：Senhwa Biosciences, Inc.

  公开号：US20210046071A1

  公开（公告）日：2021-02-18

  The present invention includes 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) or a pharmaceutically acceptable salt thereof for use in treating cancer with PALB2 mutation and/or BRCA2 mutation.

  本发明涵盖2-(4-甲基-[1,4]二氮杂环己烷-1-基)-5-氧代-5H-7-硫-1,11b-二氮杂苯并[c]荧芒-6-羧酸(5-甲基吡嗪-2-基甲基)-酰胺(化合物I)或其药学上可接受的盐，用于治疗PALB2突变和/或BRCA2突变引起的癌症。
• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：BROWN Dennis M.

  公开号：US20160045502A1

  公开（公告）日：2016-02-18

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

  本发明描述了一种改善先前受到治疗性能不佳限制的治疗剂的治疗效果的方法和组合物，通过改善单药疗法的功效或减少副作用。这种方法和组合物特别适用于芥子碱基烷基化剂，例如尿嘧啶芥和其类似物、衍生物或前药，包括6-甲基尿嘧啶芥和6-乙基尿嘧啶芥。
• Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
  申请人：Del Mar Pharmaceuticals (BC) Ltd.

  公开号：US10201521B2

  公开（公告）日：2019-02-12

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

  二氢半乳糖醇的使用为治疗多形性胶质母细胞瘤和髓母细胞瘤提供了一种新的治疗方法。二氢半乳糖醇是一种 DNA 烷基化剂，可产生 N7 甲基化。Dianhydrogalactitol 能有效抑制癌症干细胞的生长，并对替莫唑胺难治性肿瘤有效；该药物的作用不受 MGMT 修复机制的影响。